Recruiting × Interventional × Urinary Bladder Neoplasms × Clear all FORAGER-2
Phase 3 Recruiting
450 enrolled
MK-3120-003
Phase 1/2 Recruiting
45 enrolled
Intravesical GEM/DOCE for HR BCG-Unresponsive NMIBC
Phase 2 Recruiting
174 enrolled
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
Phase 2 Recruiting
314 enrolled
ADAPT-BLADDER
Phase 1/2 Recruiting
55 enrolled
A Phase 1, Open-label Trial of Belzupacap Sarotalocan (AU-011) in Bladder Cancer
Phase 1 Recruiting
55 enrolled
Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial
Phase 2 Recruiting
160 enrolled
Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy
Phase 2/3 Recruiting
470 enrolled
IMGeS
Phase 2 Recruiting
82 enrolled
The Vanguard Study: Testing a New Way to Screen for Cancer
Phase NA Recruiting
24,000 enrolled
Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial
Phase 2 Recruiting
111 enrolled
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas
Phase 1 Recruiting
160 enrolled
MK-3475-04D
Phase 1/2 Recruiting
55 enrolled
TroFuse-031
Phase 3 Recruiting
590 enrolled
Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC
Phase 2 Recruiting
325 enrolled
panSOHO
Phase 2 Recruiting
111 enrolled
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study
Phase 3 Recruiting
486 enrolled
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
Phase 1 Recruiting
1,006 enrolled
GAIN-BCG
Phase 3 Recruiting
330 enrolled
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
Phase 1 Recruiting
310 enrolled
A Study to Learn About the Study Medicine PF-08052667 in People With Bladder Cancer
Phase 1 Recruiting
294 enrolled
Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer
Phase 1/2 Recruiting
132 enrolled
INTerpath-011
Phase 2 Recruiting
308 enrolled
A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
Phase 1 Recruiting
260 enrolled
DK222 Study at Hopkins
Phase 1 Recruiting
6 enrolled
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
Phase 1/2 Recruiting
159 enrolled
A Study of Radiation Therapy to Treat Solid Tumor Cancer That Has Spread to Soft Tissue
Phase NA Recruiting
26 enrolled
In-home Intravesical Chemotherapy for the Treatment of Bladder Cancer, INVITE Trial
Phase 1/2 Recruiting
40 enrolled
Perioperative Durvalumab With Neoadjuvant ddMVAC or Gemcitabine/Cisplatin in Patients With Muscle-invasive Bladder Cancer (NIAGARA-2)
Phase 3 Recruiting
150 enrolled
DutaBCa-1
Phase 2 Recruiting
95 enrolled
Urinary Tumor DNA-Guided Systemic Immunotherapy for Unresectable Very-High-Risk Non-Muscle-Invasive Bladder Cancer
Phase 2 Recruiting
53 enrolled
Bintrafusp Alfa (M7824) and PDS01ADC Alone and in Combination With Stereotactic Body Radiation Therapy (SBRT) in Adults With Metastatic Non-Prostate Genitourinary Malignancies
Phase 1 Recruiting
100 enrolled
18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection
Phase 2 Recruiting
320 enrolled
PRO-GAG
Phase NA Recruiting
56 enrolled
DUET-UC-NK
Phase 1 Recruiting
42 enrolled
NEXUS-01
Phase 1 Recruiting
420 enrolled
FORAGER-1
Phase 1 Recruiting
535 enrolled
EVER
Phase 3 Recruiting
540 enrolled
Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma
Phase 2/3 Recruiting
630 enrolled
Guiding Value of Urinary Tumor DNA Testing in Cystoscopy for High-Risk/Very High-Risk Non-Muscle-Invasive Bladder Cancer
Phase NA Recruiting
360 enrolled
IDO and PD-L1 Peptide Based Immune-Modulatory Therapeutic (IO102-IO103) in Combination With Pembrolizumab for BCG-Unresponsive or Intolerant, Non-Muscle Invasive Bladder Cancer
Phase 1 Recruiting
30 enrolled
PLZ4-Coated Paclitaxel-Loaded Micelles for the Treatment of Patients With Recurrent or Refractory Non-Muscle Invasive Bladder Cancer
Phase 1 Recruiting
12 enrolled
EMPOWER
Phase NA Recruiting
100 enrolled
Comprehensive Multimodal Prehabilitation Alone or With Neoadjuvant Therapy Before Major Cancer Surgery
Phase 2 Recruiting
148 enrolled
Intravesical Gemcitabine and Docetaxel for Low Grade Intermediate Risk Bladder Cancer
Phase 2 Recruiting
34 enrolled
A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors
Phase 1 Recruiting
258 enrolled
Telehealth Intervention for Ostomy Self-Management
Phase 2 Recruiting
150 enrolled
Guiding Value of Urinary Tumor DNA Testing in Repeat Transurethral Resection of Non-Muscle-Invasive Bladder Cancer
Phase NA Recruiting
196 enrolled
A Home-Based Prehabilitation Exercise Intervention for Improving Physical Function in Patients With Bladder Cancer and Upper Tract Urothelial Cancer, Get Moving Trial
Phase NA Recruiting
128 enrolled
IDOV-Immune for Advanced Solid Tumors
Phase 1 Recruiting
78 enrolled